April edition of Australian Prescriber out now
The latest issue of Australia's free, national, independent journal of drugs and therapeutics, Australian Prescriber, is now available. Some of the highlights of the April issue include:
Acute rheumatic fever and rheumatic heart disease are rare in affluent societies yet high rates persist among Aboriginal and Torres Strait Islander populations, especially those living in rural or remote settings. Repeated or severe acute rheumatic fever episodes lead to rheumatic heart disease, a form of valvular heart disease, with high morbidity and mortality.
Dr Anna Ralph, senior clinical research fellow from Menzies School of Health Research, Charles Darwin University, and colleagues from RHDAustralia, examine this important problem. They outline recent changes in Australian recommendations for antibiotic use, aspirin dose and prevention of endocarditis.
With the explosion of newly approved drugs for hepatitis C, Australia has the potential to eradicate this disease in the next 10–15 years. Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney, says new cases of hepatitis will become rare and rates of hepatitis C-related advanced liver disease, liver failure, liver cancer and liver transplantation will decrease. “It is essential that all medical practitioners, particularly GPs, have the skills to diagnose patients with hepatitis C and either manage them with specialist support if needed, or refer them for specialist care.”
The cause of rheumatoid arthritis might still be unknown, but an understanding of its pathological processes has advanced greatly in the last 20 years. Dr Tom Wilsdon, clinical pharmacology registrar at Flinders Medical Centre, and Professor Catherine Hill from the School of Medicine, University of Adelaide write that new drugs have markedly changed the way the disease is managed and as a result have improved outcomes for patients.
Other articles in the April Australian Prescriber include:
- New drug: Ceritinib for non-small cell lung cancer
- An insightful editorial examining consumer medicine information
- Economic evaluation of medicines
- Medical mishap: Proton pump inhibitor-associated hypomagnesaemia and hypocalcaemia
To read the full issue visit nps.org.au/australianprescriber.
Australian Prescriber is an independent peer-reviewed journal providing critical commentary on therapeutic topics for health professionals, particularly doctors in general practice. It is published every two months and distributed to health professionals free of charge, and is also available online at www.australianprescriber.com
If you are a journalist seeking comment on a story or more information on any of our programs or campaigns please contact our media team on 02 8217 8667 (during office hours) or call the NPS MedicineWise media phone on 0419 618 365 (for urgent media requests outside of office hours). If your enquiry is not urgent you can also send us an email.